Literature DB >> 712191

Modification of experimental renal hypertension in the rat by indomethacin and hydralazine.

J L Cangiano, C Rodriguez-Sargent, M Martinez-Maldonado.   

Abstract

The effects of pretreatment with l, H, and a combination, Hl, were assessed in rats made hypertensive by LRA. SBP, PRA, and urinary sodium and potassium excretion were measured 7 days and 1 day before LRA and 2 and 7 days after LRA on a fixed sodium diet. SBP increased 2 days after LRA in C rats, l- and Hl-treated rats but not in H-treated rats. The elevation of SBP was higher in the l group than in the C group. Hl showed a greater increase than H but less than C. PRA levels did not correlate with changes in SBP. PRA first increased 7 days after LRA. A highly significant decrease in sodium and potassium excretion was observed 7 days after LRA in C and l-treated rats. The data suggest that hydralazine may control blood pressure in this model by preventing sodium retention or, alternatively, that it may reduce blood pressure by direct peripheral vasodilation. Since natriuresis and vasodilation are two well-known effects of PGs, the results are compatible with the possibility that l exerted its noxious effect by inhibiting the synthesis of these compounds. It is also suggested by these studies that the renin angiotensin system does not play a central role in the acceleration of hypertension after l administration.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 712191

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  2 in total

1.  The effects of nifedipine on platelet aggregation and plasma 6-keto-PGF1 alpha, and its interaction with indomethacin.

Authors:  M B Murphy; M A Orchard; E L Conway; S E Barrow
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

2.  Increased levels of prostaglandin-like material in the canine blood during arterial hypotension produced by hydralazine, dihydralazine and minoxidil.

Authors:  G Haeusler; M Gerold
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-12       Impact factor: 3.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.